166 related articles for article (PubMed ID: 17867578)
1. [DNA methylation: potential for diagnosis, prognosis and therapy--prediction in oncology].
Haedicke W; Lesche R
Verh Dtsch Ges Pathol; 2006; 90():39-45. PubMed ID: 17867578
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
3. Circulating methylated DNA.
Herman JG
Ann N Y Acad Sci; 2004 Jun; 1022():33-9. PubMed ID: 15251936
[TBL] [Abstract][Full Text] [Related]
4. Use of DNA methylation for cancer detection: promises and challenges.
Zhu J; Yao X
Int J Biochem Cell Biol; 2009 Jan; 41(1):147-54. PubMed ID: 18834953
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
7. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
8. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.
Hoffmann AC; Kaifi JT; Vallböhmer D; Yekebas E; Grimminger P; Leers JM; Izbicki JR; Hölscher AH; Schneider PM; Metzger R; Brabender J
J Surg Oncol; 2009 Oct; 100(5):414-7. PubMed ID: 19653236
[TBL] [Abstract][Full Text] [Related]
9. Oncogenes and oncoproteins as tumor markers.
Pillai R
Eur J Surg Oncol; 1992 Oct; 18(5):417-24. PubMed ID: 1426290
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
11. CpG islands: their potential as biomarkers for cancer.
Shi H; Wang MX; Caldwell CW
Expert Rev Mol Diagn; 2007 Sep; 7(5):519-31. PubMed ID: 17892361
[TBL] [Abstract][Full Text] [Related]
12. Molecular detection of gene mutations and methylation abnormalities: applications in solid tumor diagnosis.
Kraus A; Schuermann M
Expert Rev Mol Diagn; 2002 Mar; 2(2):97-108. PubMed ID: 11962346
[TBL] [Abstract][Full Text] [Related]
13. [Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer].
Grote HJ
Verh Dtsch Ges Pathol; 2006; 90():216-26. PubMed ID: 17867600
[TBL] [Abstract][Full Text] [Related]
14. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.
Barton CA; Hacker NF; Clark SJ; O'Brien PM
Gynecol Oncol; 2008 Apr; 109(1):129-39. PubMed ID: 18234305
[TBL] [Abstract][Full Text] [Related]
16. Methylated genes as new cancer biomarkers.
Duffy MJ; Napieralski R; Martens JW; Span PN; Spyratos F; Sweep FC; Brunner N; Foekens JA; Schmitt M;
Eur J Cancer; 2009 Feb; 45(3):335-46. PubMed ID: 19138839
[TBL] [Abstract][Full Text] [Related]
17. Gene promoter methylation--a potential cancer marker.
Ze-Jun- L; Masato M
Adv Clin Path; 2002 Jan; 6(1):43-6. PubMed ID: 17582948
[No Abstract] [Full Text] [Related]
18. DNA methylation and cancer diagnosis: new methods and applications.
Dehan P; Kustermans G; Guenin S; Horion J; Boniver J; Delvenne P
Expert Rev Mol Diagn; 2009 Oct; 9(7):651-7. PubMed ID: 19817550
[TBL] [Abstract][Full Text] [Related]
19. Methylation status of genes in papillary thyroid carcinoma.
Smith JA; Fan CY; Zou C; Bodenner D; Kokoska MS
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1006-11. PubMed ID: 17938324
[TBL] [Abstract][Full Text] [Related]
20. Comparative promoter methylation analysis of p53 target genes in urogenital cancers.
Christoph F; Hinz S; Weikert S; Kempkensteffen C; Schostak M; Miller K; Schrader M
Urol Int; 2008; 80(4):398-404. PubMed ID: 18587251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
